Market Closed -
Other stock markets
|
After market 01:29:32 pm | |||
29.17 EUR | -0.38% | 29.09 | -0.27% |
May. 28 | FMC briefly burdened by research success in the fight against diabetes | DP |
May. 24 | FMC, Fresenius and Davita rise after Ozempic news | DP |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.84 for the current year.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.31% | 17.88B | A- | ||
+25.52% | 88.99B | C+ | ||
-24.52% | 74.82B | B- | ||
+0.49% | 26.63B | C+ | ||
-14.25% | 16.43B | B | ||
+2.97% | 15.77B | A- | ||
+79.20% | 13.21B | C+ | ||
+70.11% | 13.08B | C- | ||
+40.44% | 12.9B | B- | ||
+24.51% | 12.7B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FRE Stock
- Ratings Fresenius SE & Co. KGaA